Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-018427
Filing Date
2023-11-09
Accepted
2023-11-09 08:05:32
Documents
53
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ewtx-20230930x10q.htm   iXBRL 10-Q 1969396
2 EX-31.1 ewtx-20230930xex31d1.htm EX-31.1 19406
3 EX-31.2 ewtx-20230930xex31d2.htm EX-31.2 19219
4 EX-32.1 ewtx-20230930xex32d1.htm EX-32.1 7541
5 EX-32.2 ewtx-20230930xex32d2.htm EX-32.2 7618
  Complete submission text file 0001558370-23-018427.txt   6057228

Data Files

Seq Description Document Type Size
6 EX-101.SCH ewtx-20230930.xsd EX-101.SCH 31849
7 EX-101.CAL ewtx-20230930_cal.xml EX-101.CAL 37223
8 EX-101.DEF ewtx-20230930_def.xml EX-101.DEF 130494
9 EX-101.LAB ewtx-20230930_lab.xml EX-101.LAB 327937
10 EX-101.PRE ewtx-20230930_pre.xml EX-101.PRE 236299
47 EXTRACTED XBRL INSTANCE DOCUMENT ewtx-20230930x10q_htm.xml XML 898804
Mailing Address 1715 38TH ST BOULDER CO 80301
Business Address 1715 38TH ST BOULDER CO 80301 720-262-7002
Edgewise Therapeutics, Inc. (Filer) CIK: 0001710072 (see all company filings)

EIN.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40236 | Film No.: 231390164
SIC: 2834 Pharmaceutical Preparations